[THE INVESTOR] Korean biotechnology firm Panagene said on Oct. 26 that the country’s health regulator has granted approval for sale of its diagnostics kit for sexually transmitted diseases.
The product -- PANARealTyper TM STD Detection kit -- detects 12 types of pathogenic bacteria causing STDs by a single probe.
The company has applied its technology named PANARealTyper, which is a multiplex melting curve analysis using fluorescence labeled PNA probe, to the kit.
In 2016, Panagene launched a diagnostic tool for human papillomavirus using the same technology.
The Ministry of Food and Drug Safety’s approval is a milestone for the company which is seeking to expand its product portfolio to go beyond cancer diagnosis, the Daejeon-based firm said.
“Starting with the STD kit, we will pursue market expansion here and overseas by releasing new products,” a company official said.
Last year, Panagene introduced liquid biopsy lung cancer diagnosis kit called PANAMutyper R EGFR that enables the detection of as little as 0.1 percent mutant allele, seeking to replace painful tumor tissue extract tests.
By Park Han-na (firstname.lastname@example.org)